PL2358686T3 - Arylometylobenzochinazolinonowe dodatnie modulatory allostertyczne receptora M1 - Google Patents

Arylometylobenzochinazolinonowe dodatnie modulatory allostertyczne receptora M1

Info

Publication number
PL2358686T3
PL2358686T3 PL09761104T PL09761104T PL2358686T3 PL 2358686 T3 PL2358686 T3 PL 2358686T3 PL 09761104 T PL09761104 T PL 09761104T PL 09761104 T PL09761104 T PL 09761104T PL 2358686 T3 PL2358686 T3 PL 2358686T3
Authority
PL
Poland
Prior art keywords
positive allosteric
receptor positive
allosteric modulators
aryl methyl
methyl benzoquinazolinone
Prior art date
Application number
PL09761104T
Other languages
English (en)
Inventor
Scott D Kuduk
Douglas C Beshore
Marco Christina Di
Thomas J Greshock
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PL2358686T3 publication Critical patent/PL2358686T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/19—Acids containing three or more carbon atoms
    • C07C53/21—Acids containing three or more carbon atoms containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL09761104T 2008-11-20 2009-11-19 Arylometylobenzochinazolinonowe dodatnie modulatory allostertyczne receptora M1 PL2358686T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19974008P 2008-11-20 2008-11-20
PCT/US2009/065060 WO2010059773A1 (en) 2008-11-20 2009-11-19 Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
EP09761104A EP2358686B1 (en) 2008-11-20 2009-11-19 Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators

Publications (1)

Publication Number Publication Date
PL2358686T3 true PL2358686T3 (pl) 2013-02-28

Family

ID=41565956

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09761104T PL2358686T3 (pl) 2008-11-20 2009-11-19 Arylometylobenzochinazolinonowe dodatnie modulatory allostertyczne receptora M1

Country Status (36)

Country Link
US (4) US8557832B2 (pl)
EP (1) EP2358686B1 (pl)
JP (1) JP5102397B2 (pl)
KR (1) KR101305590B1 (pl)
CN (1) CN102292323B (pl)
BR (1) BRPI0921924A2 (pl)
CA (1) CA2743562C (pl)
CO (1) CO6361928A2 (pl)
CR (1) CR20110268A (pl)
CY (1) CY1113665T1 (pl)
DK (1) DK2358686T3 (pl)
DO (1) DOP2011000135A (pl)
EA (1) EA019098B1 (pl)
EC (1) ECSP11011066A (pl)
ES (1) ES2393694T3 (pl)
GE (1) GEP20156348B (pl)
GT (1) GT201100127A (pl)
HN (1) HN2011001358A (pl)
HR (1) HRP20120992T1 (pl)
IL (1) IL212573A (pl)
MA (1) MA32898B1 (pl)
MX (1) MX2011005284A (pl)
MY (1) MY162502A (pl)
NI (1) NI201100100A (pl)
NZ (1) NZ592961A (pl)
PE (1) PE20120031A1 (pl)
PL (1) PL2358686T3 (pl)
PT (1) PT2358686E (pl)
RS (1) RS52528B (pl)
SG (1) SG171769A1 (pl)
SI (1) SI2358686T1 (pl)
SV (1) SV2011003912A (pl)
TN (1) TN2011000209A1 (pl)
UA (1) UA100459C2 (pl)
WO (1) WO2010059773A1 (pl)
ZA (1) ZA201103612B (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101651312B1 (ko) * 2009-08-31 2016-08-25 머크 샤프 앤드 돔 코포레이션 피라닐 아릴 메틸 벤조퀴나졸리논 ｍ1 수용체 양성 알로스테릭 조절제
EP2490692B1 (en) 2009-10-21 2016-11-16 Merck Sharp & Dohme Corp. Quinolinone-pyrazolone m1 receptor positive allosteric modulators
US8664387B2 (en) * 2009-12-14 2014-03-04 Merck Sharp & Dohme Corp. Pyridoquinazolinone M1 receptor positive allosteric modulators
PH12012501222A1 (en) 2009-12-17 2012-11-05 Merck Sharp & Dohme Quinoline amide m1 receptor positive allosteric modulators
EP2515656B1 (en) * 2009-12-21 2014-08-06 Merck Sharp & Dohme Corp. Aminobenzoquinazolinone m1 receptor positive allosteric modulators
US8557992B2 (en) 2010-06-15 2013-10-15 Merck Sharp & Dohme Corp. Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators
WO2012003147A1 (en) 2010-07-01 2012-01-05 Merck Sharp & Dohme Corp. Isoindolone m1 receptor positive allosteric modulators
WO2012047702A1 (en) * 2010-10-04 2012-04-12 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
EP2709624B1 (en) * 2011-05-17 2016-04-27 Merck Sharp & Dohme Corp. N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
JP2014522873A (ja) 2011-08-12 2014-09-08 ビーエーエスエフ ソシエタス・ヨーロピア アントラニルアミド化合物および殺虫剤としてのその使用
AR088786A1 (es) 2011-08-12 2014-07-10 Basf Se Compuestos de antranilamida y sus usos como plaguicidas
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
WO2013105117A1 (en) * 2012-01-10 2013-07-18 Council Of Scientific & Industrial Research Cu-MEDIATED ANNULATION FOR THE PRODUCTION OF 1-AMINO-2-NAPHTHALENECARBOXYLIC ACID DERIVATIVES
EP2821401B1 (en) 2012-03-02 2020-09-09 Takeda Pharmaceutical Company Limited Dihydroquinolinone compounds as modulators of the muscarininc m1 receptor
EP2921480B1 (en) 2012-11-19 2017-10-11 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
JP6540690B2 (ja) * 2014-04-17 2019-07-10 住友化学株式会社 ニトロ化合物の製造方法
EP3265466A4 (en) * 2015-03-06 2018-12-26 Chase Pharmaceuticals Corporation Peripheral-anticholinergic muscarinic agonist combination
KR20180019234A (ko) 2015-06-26 2018-02-23 다케다 야쿠힌 고교 가부시키가이샤 콜린성 무스카린 m1 수용체의 조절제로서의 2,3-디히드로-4h-1,3-벤족사진-4-온 유도체
WO2017044693A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
EP3356332A4 (en) 2015-09-30 2019-06-19 Merck Sharp & Dohme Corp. METHOD FOR PRODUCING POSITIVE ALLOSTERIC M1 RECEPTOR MODULATORS
WO2017058689A1 (en) * 2015-09-30 2017-04-06 Merck Sharp & Dohme Corp. Crystal forms of a m1 receptor positive allosteric modulator
JP6787913B2 (ja) * 2015-10-20 2020-11-18 武田薬品工業株式会社 複素環化合物
ES2793239T3 (es) 2016-04-15 2020-11-13 Abbvie Inc Inhibidores del bromodominio
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
EP3525588B1 (en) 2016-10-14 2024-04-24 PI Industries Ltd 4-substituted phenylamidine derivatives and their use to protect crops by fighting undesired phytopathogenic micoorganisms
JP7139323B2 (ja) 2016-11-01 2022-09-20 エフ．ホフマン－ラ ロシュ アーゲー Ｃｎｓ関連疾患を処置するための１，３－ジヒドロ－１，４－ベンゾジアゼピン－２－チオン
WO2018212312A1 (ja) 2017-05-19 2018-11-22 武田薬品工業株式会社 スクリーニング方法
BR112021005759A2 (pt) 2018-09-28 2021-07-06 Takeda Pharmaceuticals Co composto, medicamento, métodos de modulação alostérica positiva e para a profilaxia ou o tratamento de constipação, e, uso do composto ou de um sal do mesmo
KR20230158657A (ko) 2021-03-18 2023-11-21 메르크 파텐트 게엠베하 유기 전계 발광 디바이스용 헤테로방향족 화합물
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
WO2026051746A1 (zh) * 2024-09-06 2026-03-12 四川科伦药物研究院有限公司 化合物、包含其的药物组合物及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0856001B1 (en) * 1995-10-02 2002-08-28 F. Hoffmann-La Roche Ag Pyrimidine derivatives as 5ht2c receptor antagonists
AU5330698A (en) * 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
ATE302199T1 (de) * 1998-10-16 2005-09-15 Sumitomo Pharma Quinalozinon-derivate
JP2005089298A (ja) * 2001-09-18 2005-04-07 Japan Tobacco Inc ナフタレン化合物及びその医薬用途
EP1596867A4 (en) * 2003-02-19 2006-03-22 Merck & Co Inc TREATMENT OF PSYCHOSIS WITH A MUSCARIN M1 RECEPTOR ECTOPIC ACTIVATOR
MX2007013606A (es) * 2005-05-04 2007-12-10 Hoffmann La Roche (3,4-dihidro-quinazolin2-il)-(2-ariloxi-etil)-aminas que tienen una actividad en el receptor 5-ht.
US8178667B2 (en) * 2006-06-28 2012-05-15 Merck Sharp & Dohme Corp. Benzyl-substituted quinolone M1 receptor positive allosteric modulators
WO2012047702A1 (en) * 2010-10-04 2012-04-12 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators

Also Published As

Publication number Publication date
EA201170705A1 (ru) 2011-12-30
CN102292323A (zh) 2011-12-21
US9708273B2 (en) 2017-07-18
US20160229813A1 (en) 2016-08-11
HN2011001358A (es) 2014-03-03
DOP2011000135A (es) 2011-07-31
EA019098B1 (ru) 2014-01-30
EP2358686B1 (en) 2012-09-26
IL212573A0 (en) 2011-06-30
US8557832B2 (en) 2013-10-15
SG171769A1 (en) 2011-07-28
HK1154587A1 (en) 2012-04-27
ZA201103612B (en) 2012-01-25
UA100459C2 (en) 2012-12-25
US8883810B2 (en) 2014-11-11
HRP20120992T1 (hr) 2012-12-31
CA2743562A1 (en) 2010-05-27
CN102292323B (zh) 2014-12-24
AU2009316578A1 (en) 2011-06-23
MY162502A (en) 2017-06-15
PT2358686E (pt) 2012-12-06
NZ592961A (en) 2012-09-28
KR20110073596A (ko) 2011-06-29
KR101305590B1 (ko) 2013-09-09
JP2012509343A (ja) 2012-04-19
MX2011005284A (es) 2011-06-17
JP5102397B2 (ja) 2012-12-19
RS52528B (sr) 2013-04-30
WO2010059773A1 (en) 2010-05-27
SI2358686T1 (sl) 2013-05-31
PE20120031A1 (es) 2012-02-05
CR20110268A (es) 2011-07-01
GEP20156348B (en) 2015-08-25
SV2011003912A (es) 2011-10-13
EP2358686A1 (en) 2011-08-24
US20150031713A1 (en) 2015-01-29
MA32898B1 (fr) 2011-12-01
DK2358686T3 (da) 2013-01-07
US20110224198A1 (en) 2011-09-15
GT201100127A (es) 2014-02-10
CY1113665T1 (el) 2016-06-22
ECSP11011066A (es) 2011-06-30
NI201100100A (es) 2011-09-12
CO6361928A2 (es) 2012-01-20
US20140005182A1 (en) 2014-01-02
BRPI0921924A2 (pt) 2015-12-29
CA2743562C (en) 2014-03-18
TN2011000209A1 (en) 2012-12-17
ES2393694T3 (es) 2012-12-27
IL212573A (en) 2015-01-29

Similar Documents

Publication Publication Date Title
ZA201103612B (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
ZA201201205B (en) Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
ZA201204313B (en) Quinoline amide m1 receptor positive allosteric modulators
EP2501231A4 (en) POSITIVE ALLOSTERIC CHINOLIZIDINONE CARBOXAMIDE M1 RECEPTOR MODULATORS
EP2490692A4 (en) CHINOLINONE PYRAZOLON M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
BRPI0923305A2 (pt) moduladores de receptores toll-like
DK2297100T3 (da) Tetrahydrocyclopenta[b]indol-androgenreceptor-modulatorer
EP2179061A4 (en) GREAT LIKE RECEPTOR MODULATORS
IL209710A0 (en) Self-configuration for femtocells
IL200922A0 (en) 8-oxy-quinoline derivatives as bradykinin b2 receptor modulators
EP2287673A4 (en) TONER
IL211170A0 (en) Mif modulators
EP2344446A4 (en) S1P RECEPTOR MODULATORS
EP2312949A4 (en) POSITIVE N-HETEROCYCLIC ALLOSTERIC M1 RECEPTOR MODULATORS
EP2256557A4 (en) TONER
GB0701992D0 (en) Grehlin Receptor Modulators
GB201004739D0 (en) Receptor modulators
EP2512245A4 (en) POSITIVE ALLOSTERIC PYRIDOCHINOLICIDIDINE M1 RECEPTOR MODULATORS
EP2252151A4 (en) POSITIVE ALLOSTERIC CHINOLIZIDINONE M1 RECEPTOR MODULATORS
IL204786A0 (en) Benzyl - cycloalkyl sphingosing 1 - phosphate receptor modulators
EP2355659A4 (en) Fused Hetereocyclic M1 Receptor Positive Allosmatic Modulators
ZA201303950B (en) Glucagon receptor modulators
EP2340247A4 (en) POSITIVE ALLOSTERIC MODULATORS OF THE CHINOLIZIDINONE M1 RECEPTOR
EP2268280A4 (en) POSITIVE ALLOSTERIC CHINOLIZIDINONE M1 RECEPTOR MODULATORS
GB0811212D0 (en) CB1 Receptor Modulators